NCT06955988 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Locally Advanced or Metastatic Non-small Cell Lung Cancer

Interventions

DRUG

AST2303 Tablets(ABK3376 Tablets) ，25mg

Usage and dosage: 25mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle

DRUG

AST2303 Tablets(ABK3376 Tablets) ，50mg

Usage and dosage: 50mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle

DRUG

AST2303 Tablets(ABK3376 Tablets) ，75mg

Usage and dosage: 75mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle

DRUG

AST2303 Tablets(ABK3376 Tablets) ，100mg

Usage and dosage: 100mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle

DRUG

AST2303 Tablets(ABK3376 Tablets) ，125mg

Usage and dosage: 125mg, oral on an empty stomach Duration of medication: oral once a day, 21 days as a cycle

Trial Locations (1)

RECRUITING

Shanghai Chest Hospital, Shanghai